Overall, these findings suggest that MGMT methylation is associated with improved survival but an increased risk of out-field recurrence, while EGFR amplification is linked to higher rates of marginal recurrence, potentially reflecting a more invasive tumor phenotype. This evidence concerns the gene EGFR and neoplasm.